These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 34459025)

  • 21. Omecamtiv mercabil and blebbistatin modulate cardiac contractility by perturbing the regulatory state of the myosin filament.
    Kampourakis T; Zhang X; Sun YB; Irving M
    J Physiol; 2018 Jan; 596(1):31-46. PubMed ID: 29052230
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Omecamtiv Mecarbil Slows Myosin Kinetics in Skinned Rat Myocardium at Physiological Temperature.
    Kieu TT; Awinda PO; Tanner BCW
    Biophys J; 2019 Jun; 116(11):2149-2160. PubMed ID: 31103235
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure.
    Teerlink JR; Diaz R; Felker GM; McMurray JJV; Metra M; Solomon SD; Adams KF; Anand I; Arias-Mendoza A; Biering-Sørensen T; Böhm M; Bonderman D; Cleland JGF; Corbalan R; Crespo-Leiro MG; Dahlström U; Echeverria LE; Fang JC; Filippatos G; Fonseca C; Goncalvesova E; Goudev AR; Howlett JG; Lanfear DE; Li J; Lund M; Macdonald P; Mareev V; Momomura SI; O'Meara E; Parkhomenko A; Ponikowski P; Ramires FJA; Serpytis P; Sliwa K; Spinar J; Suter TM; Tomcsanyi J; Vandekerckhove H; Vinereanu D; Voors AA; Yilmaz MB; Zannad F; Sharpsten L; Legg JC; Varin C; Honarpour N; Abbasi SA; Malik FI; Kurtz CE;
    N Engl J Med; 2021 Jan; 384(2):105-116. PubMed ID: 33185990
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sex differences in stretch-dependent effects on tension and Ca(2+) transient of rat trabeculae in monocrotaline pulmonary hypertension.
    Lookin O; Kuznetsov D; Protsenko Y
    J Physiol Sci; 2015 Jan; 65(1):89-98. PubMed ID: 25359385
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of omecamtiv mecarbil on calcium-transients and contractility in a translational canine myocyte model.
    Gao B; Sutherland W; Vargas HM; Qu Y
    Pharmacol Res Perspect; 2020 Oct; 8(5):e00656. PubMed ID: 32969560
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Endostatin is protective against monocrotaline-induced right heart disease through the inhibition of T-type Ca(2+) channel.
    Imoto K; Kumatani S; Okada M; Yamawaki H
    Pflugers Arch; 2016 Jul; 468(7):1259-1270. PubMed ID: 27023352
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Reduced inotropic effect of nifekalant in failing hearts in rats.
    Endo H; Miura M; Hirose M; Takahashi J; Nakano M; Wakayama Y; Sugai Y; Kagaya Y; Watanabe J; Shirato K; Shimokawa H
    J Pharmacol Exp Ther; 2006 Sep; 318(3):1102-7. PubMed ID: 16738208
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combined Therapy With Dobutamine and Omecamtiv Mecarbil in Pigs With Ischemic Acute Heart Failure Is Attributed to the Effect of Dobutamine.
    Rødland L; Rønning L; Kildal AB; Myrmel T; How OJ
    J Cardiovasc Pharmacol Ther; 2020 May; 25(3):232-239. PubMed ID: 31645117
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cardiac Myosin Activator Omecamtiv Mecarbil: Novel Treatment for Systolic Heart Failure.
    Mack M; Frishman WH
    Cardiol Rev; 2024 Jul-Aug 01; 32(4):378-383. PubMed ID: 36946979
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Omecamtiv mecarbil activates ryanodine receptors from canine cardiac but not skeletal muscle.
    Nánási P; Gaburjakova M; Gaburjakova J; Almássy J
    Eur J Pharmacol; 2017 Aug; 809():73-79. PubMed ID: 28506910
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Omecamtiv mecarbil treatment improves post-resuscitation cardiac function and neurological outcome in a rat model.
    Wu SN; Tsai MS; Huang CH; Chen WJ
    PLoS One; 2022; 17(2):e0264165. PubMed ID: 35176110
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dilated cardiomyopathy mutation in the converter domain of human cardiac myosin alters motor activity and response to omecamtiv mecarbil.
    Tang W; Unrath WC; Desetty R; Yengo CM
    J Biol Chem; 2019 Nov; 294(46):17314-17325. PubMed ID: 31578282
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dose-dependent augmentation of cardiac systolic function with the selective cardiac myosin activator, omecamtiv mecarbil: a first-in-man study.
    Teerlink JR; Clarke CP; Saikali KG; Lee JH; Chen MM; Escandon RD; Elliott L; Bee R; Habibzadeh MR; Goldman JH; Schiller NB; Malik FI; Wolff AA
    Lancet; 2011 Aug; 378(9792):667-75. PubMed ID: 21856480
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Omecamtiv Mecarbil in Chronic Heart Failure With Reduced Ejection Fraction: Rationale and Design of GALACTIC-HF.
    Teerlink JR; Diaz R; Felker GM; McMurray JJV; Metra M; Solomon SD; Legg JC; Büchele G; Varin C; Kurtz CE; Malik FI; Honarpour N
    JACC Heart Fail; 2020 Apr; 8(4):329-340. PubMed ID: 32035892
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Omecamtiv Mecarbil Abolishes Length-Mediated Increase in Guinea Pig Cardiac Myofiber Ca
    Gollapudi SK; Reda SM; Chandra M
    Biophys J; 2017 Aug; 113(4):880-888. PubMed ID: 28834724
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Perspectives of a myosin motor activator agent with increased selectivity.
    Nánási P; Komáromi I; Almássy J
    Can J Physiol Pharmacol; 2018 Jul; 96(7):676-680. PubMed ID: 29792814
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Myosin from the ventricle is more sensitive to omecamtiv mecarbil than myosin from the atrium.
    Shchepkin DV; Nabiev SR; Nikitina LV; Kochurova AM; Berg VY; Bershitsky SY; Kopylova GV
    Biochem Biophys Res Commun; 2020 Aug; 528(4):658-663. PubMed ID: 32513536
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of the Novel Myotrope Danicamtiv on Cross-Bridge Behavior in Human Myocardium.
    Choi J; Holmes JB; Campbell KS; Stelzer JE
    J Am Heart Assoc; 2023 Oct; 12(20):e030682. PubMed ID: 37804193
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Positive cardiac inotrope omecamtiv mecarbil activates muscle despite suppressing the myosin working stroke.
    Woody MS; Greenberg MJ; Barua B; Winkelmann DA; Goldman YE; Ostap EM
    Nat Commun; 2018 Sep; 9(1):3838. PubMed ID: 30242219
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Myocardial force development and structural changes associated with monocrotaline induced cardiac hypertrophy and heart failure.
    Korstjens IJ; Rouws CH; van der Laarse WJ; Van der Zee L; Stienen GJ
    J Muscle Res Cell Motil; 2002; 23(1):93-102. PubMed ID: 12363290
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.